Inhibiteurs des PARP pour le traitement du cancer épithélial de l’ovaire et des trompes de Fallope
Inhibiteurs des PARP pour le traitement du cancer épithélial de l’ovaire et des trompes de Fallope
Embedded Files
Présenté par Dre Diane Provencher, Professeure titulaire d’obstétrique-gynécologie, Université de Montréal et Directrice – Recherche en cancer de l’ovaire, Institut du cancer de Montréal.
PARP Inhibitors for Epithelial Ovarian Cancer
PARP Inhibitors for Epithelial Ovarian Cancer
Dr. Alon Altman summarizes the Canadian consensus paper on first-line PARPi maintenance for advanced, high-grade serous and endometrioid tubal, ovarian, and primary peritoneal cancers.
RevealingNewDataIn_BC_May20_22.pptxHER2+ Metastatic Breast Cancer Paper: Canadian Perspective Program
HER2+ Metastatic Breast Cancer Paper: Canadian Perspective Program
Program summarizing the Canadian perspective paper on a new treatment algorithm for HER2+ Breast Cancer.
RevealingNewDataIn_BC_May20_22_FR.pptxTraitement du cancer du sein HER2-positif de stade avancé
Traitement du cancer du sein HER2-positif de stade avancé
Programme sur la tratement du cancer du sein HER2-positif.
MBC AE Nursing Program_April27_21.pptxHER2+ Metastatic Breast Cancer: Management of Adverse Events
HER2+ Metastatic Breast Cancer: Management of Adverse Events
Nursing program on managing AEs with ADCs and TKIs. Funding provided by AstraZeneca.
RWE Education program_FINAL_Dec5-19_FINAL.pptxReal-World Evidence in Inflammatory Arthritis
Real-World Evidence in Inflammatory Arthritis
Program highlighting real-world evidence in inflammatory arthritis.
SCNursingProgram_Jan27_17.pptxSC Rituximab Nursing Program
SC Rituximab Nursing Program
**Funding for our medical education programs provided by AstraZeneca and Janssen
Report abuse